



ASX/media release

9 November 2006

AtCor Medical optimistic about future demand

At the annual general meeting of AtCor Medical Holdings Limited (ASX:ACG), chairman Donal O'Dwyer said that AtCor had made a great deal of progress to position itself for greater revenues from its SphygmoCor[®] system, which measures central blood pressure non-invasively.

He emphasised the impact of major clinical study results confirming the significance of central heart pressures to the management of cardiovascular disease. These conclusions were central in the June 2006 decision by the United Kingdom's National Institute for Health and Clinical Excellence (NICE) and British Hypertension Society (BHS) to recommend changing drug therapy for an estimated 2 million patients. The new recommendations stated that beta-blockers should not be used to treat high blood pressure, except in specific cases. This decision was only possible because of the information and data provided by SphygmoCor.

Providing an update on AtCor's progress in the United States, AtCor chief executive officer Duncan Ross said the company had a strong market opportunity in the pharmaceutical sector, and was on track to more than double US revenues. AtCor has had a robust start to the financial year, gaining the single largest order in the company's history - a US\$1.5 million sale to a mid-sized US pharmaceutical company. In addition, AtCor has more than doubled its sales opportunity pipeline from under US\$1.0 million to over US\$2.5 million.

Duncan Ross succeeded Ross Harricks today as chief executive officer, and was appointed to the company's board. Ross Harricks continues as an executive director and will focus on developing corporate relationships.

"I would like to thank Ross Harricks at this time for his vision, determination and energy during the company's early stages and the effort and leadership he has provided to bring AtCor to this point," said Donal O'Dwyer.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
(02) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial & Corporate Relations
Ph: (02) 8264 1004/m. 0407 231 282 or a.rambukwella@fcr.com.au